Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Pediatrics. 2024 Jul 5:e2024066226. doi: 10.1542/peds.2024-066226. Online ahead of print.
ABSTRACT
Pediatric emergency departments (EDs) in the United States are facing a rise in the number of children and adolescents who present with opioid use disorder (OUD), often driven by illicitly manufactured fentanyl. Medication treatment of pediatric OUD in the ED setting is often limited to symptomatic treatment of opioid withdrawal. Pediatric patients are rarely offered medications for OUD, especially in the ED setting. Buprenorphine is a partial opioid agonist that is Food and Drug Administration-approved for the treatment of OUD in patients aged 16 years and older. Adult studies have demonstrated that ED initiation of medication for OUD such as buprenorphine is feasible, safely treats withdrawal symptoms, and can improve patient compliance with outpatient follow-up. However, initiation of buprenorphine in the ED has not been well-studied in the pediatric population. We present 2 cases of adolescent patients, a 16-year-old male and 17-year-old female, who presented to the ED with opioid withdrawal. They were both diagnosed with severe OUD because of their use of counterfeit pills containing fentanyl. Both patients were successfully started on buprenorphine/naloxone in the pediatric ED before transitioning to an outpatient addiction clinic for continued treatment. The case series demonstrates the feasibility of ED-based buprenorphine initiation for adolescents, an important and timely intervention for adolescents with OUD.
PMID:38966873 | DOI:10.1542/peds.2024-066226
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study Study Protocol for Pain Self-Management and Patient-Oriented Buprenorphine Dosing for Pain and Retention in Office-Based Opioid Treatment: A Hybrid Type 1, 2 × 2 Factorial Randomized Controlled Trial "I don't think that a medication is going to help someone long-term stay off opioids": Treatment and recovery beliefs of rural Vermont family members of people with opioid use disorder Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada Comparison of 30-day retention in treatment among patients referred to opioid use disorder treatment from emergency department and telemedicine settings Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine Association between opioid use disorder and palliative care: a cohort study using linked health administrative data in Ontario, Canada Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder Neuroimaging of opioid effects in humans across conditions of acute administration, chronic pain therapy, and opioid use disorder Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl Patient experiences with telehealth treatment for opioid use disorder in Alabama Characteristics of mHealth therapy app engagement by young adults with OUD Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation Levels of engagement among office-based opioid treatment (OBOT) patients with concurrent methamphetamine use How Financial Beliefs and Behaviors Influence the Financial Health of Individuals Struggling with Opioid Use Disorder Assessing men with opioid use disorder for testosterone deficiency after the development of symptoms Pain and its Perceived Relatedness to the Onset, Maintenance, and Relapse of Opioid use Disorder: A Descriptive Study of Non-Treatment-Seeking Individuals The sociodemographic profile and the challenges associated with treatment and rehabilitation in female heroin users: A case series from Northeast India Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice Shaping and shifting schemas on supervised injectable opioid treatment: findings from a cross-sectional qualitative study in two German treatment facilities Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality The Americans with Disabilities Act and Medication Assisted Treatment in Correctional Settings How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Comparison of Opioid Use Disorder Patients with and without Problematic Internet Use in Terms of Impulsivity and Attention Deficit Hyperactivity Disorder Identification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanyl Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder in Canada Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada Change in substance use among patients in opioid maintenance treatment: baseline to 1-year follow-up Change in substance use among patients in opioid maintenance treatment: baseline to 1-year follow-up Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning Scaling Emergency Department Opioid Use Disorder Treatment Across California to Reduce Overdose Deaths, 2019-2023 Pediatric Pharmacology for the Primary Care Provider: Advances and Limitations Commentary With Study Protocol: Implementation and Effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) as an Adjunct to Methadone Treatment for Opioid Use Disorder (IMPOWR-MORE) Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults Experiences of Stigma and Discrimination Compounded by Intersecting Identities among Individuals Receiving Medication for Opioid Use Disorder Opioid use and risks in liver transplant candidates and recipients Genome-wide association study reveals multiple loci for analgesia and opioid consumption behaviors associated with heroin vulnerability in outbred rats Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone Posttraumatic stress disorder in people who use drugs: syringe services program utilization, treatment need, and preferences for onsite mental health care Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes Wiidookaage'win: Beta-test of a Facebook group intervention for native women to support opioid use recovery Impact of opioid maintenance therapy in the community on reincarceration in individuals with opioid use disorder-A linked cohort study
Evidence Blueprint
Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments Doing Our Best in a Broken System: The Urgent Need for Expansion of Medication for Opioid Use Disorder Treatments in the United States Emergency Department Access to Buprenorphine for Opioid Use Disorder At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder Buprenorphine and Opioid Use Disorder Training: Graduate Nursing Curricula Recommendations The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants Opioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention An Appraisal of Using Opioids in Patients with Opioid Use Disorder Demographics and Clinical Characteristics of Patients With Opioid Use Disorder and Offered Medication-Assisted Treatment in the Emergency Department Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs Psychotherapies in opioid use disorder: toward a step-care model Multimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review Timing of treatment for opioid use disorder among birthing people Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder Risks of opioid overdose among New York State Medicaid recipients with chronic pain before and during the COVID-19 pandemic High-deductible Health Plans and Nonfatal Opioid Overdose Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone Hospital-based opioid treatment: Expanding and sustaining the model in Texas Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population? Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder Prevention and Intervention with Young People as a Critical Public Health Strategy to Curtail the Opioid Epidemic: A Call to Action Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study Treatment of poppy seed tea misuse with buprenorphine in a telehealth practice: a case series Profiling neuronal methylome and hydroxymethylome of opioid use disorder in the human orbitofrontal cortex Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers Study Protocol for Pain Self-Management and Patient-Oriented Buprenorphine Dosing for Pain and Retention in Office-Based Opioid Treatment: A Hybrid Type 1, 2 × 2 Factorial Randomized Controlled Trial Healthcare costs and use before and after opioid overdose in Veterans Health Administration patients with opioid use disorder Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial "I don't think that a medication is going to help someone long-term stay off opioids": Treatment and recovery beliefs of rural Vermont family members of people with opioid use disorder Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada Comparison of 30-day retention in treatment among patients referred to opioid use disorder treatment from emergency department and telemedicine settings Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine Association between opioid use disorder and palliative care: a cohort study using linked health administrative data in Ontario, Canada Missed Opportunities: Substance Use Hotline Operator Uncertainty of State Buprenorphine Prescribing via Telemedicine Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder